Literature DB >> 25488897

A randomized comparative effectiveness trial of novel endoscopic techniques and approaches for Barrett's esophagus screening in the community.

Sarmed S Sami1, Kelly T Dunagan2, Michele L Johnson2, Cathy D Schleck3, Nilay D Shah4, Alan R Zinsmeister3, Louis-Michel Wongkeesong2, Kenneth K Wang2, David A Katzka2, Krish Ragunath1, Prasad G Iyer2.   

Abstract

OBJECTIVES: The objective of this study was to compare participation rates and clinical effectiveness of sedated esophagogastroduodenoscopy (sEGD) and unsedated transnasal endoscopy (uTNE) for esophageal assessment and Barrett's esophagus (BE) screening in a population-based cohort.
METHODS: This was a prospective, randomized, controlled trial in a community population. Subjects ≥50 years of age who previously completed validated gastrointestinal symptom questionnaires were randomized (stratified by age, sex, and reflux symptoms) to one of three screening techniques (either sEGD or uTNE in a mobile research van (muTNE) or uTNE in a hospital outpatient endoscopy suite (huTNE)) and invited to participate.
RESULTS: Of the 459 subjects, 209 (46%) agreed to participate (muTNE n=76, huTNE n=72, and sEGD n=61). Participation rates were numerically higher in the unsedated arms of muTNE (47.5%) and huTNE (45.7%) compared with the sEGD arm (40.7%), but were not statistically different (P=0.27). Complete evaluation of the esophagus was similar using muTNE (99%), huTNE (96%), and sEGD (100%) techniques (P=0.08). Mean recovery times (min) were longer for sEGD (67.3) compared with muTNE (15.5) and huTNE (18.5) (P<0.001). Approximately 80% of uTNE subjects were willing to undergo the procedure again in future. Respectively, 29% and 7.8% of participating subjects had esophagitis and BE.
CONCLUSIONS: Mobile van and clinic uTNE screening had comparable clinical effectiveness with similar participation rates and safety profile to sEGD. Evaluation time with uTNE was significantly shorter. Prevalence of BE and esophagitis in community subjects ≥50 years of age was substantial. Mobile and outpatient unsedated techniques may provide an effective alternative strategy to sEGD for esophageal assessment and BE screening.

Entities:  

Mesh:

Year:  2014        PMID: 25488897      PMCID: PMC4387566          DOI: 10.1038/ajg.2014.362

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  37 in total

1.  Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study.

Authors:  Smita L S Halder; G Richard Locke; Cathy D Schleck; Alan R Zinsmeister; L Joseph Melton; Nicholas J Talley
Journal:  Gastroenterology       Date:  2007-06-20       Impact factor: 22.682

2.  Prevalence of Barrett's esophagus in the general population: an endoscopic study.

Authors:  Jukka Ronkainen; Pertti Aro; Tom Storskrubb; Sven-Erik Johansson; Tore Lind; Elisabeth Bolling-Sternevald; Michael Vieth; Manfred Stolte; Nicholas J Talley; Lars Agréus
Journal:  Gastroenterology       Date:  2005-12       Impact factor: 22.682

3.  Prevalence of Barrett's Esophagus.

Authors:  Douglas K Rex; Michael Shaw; Roy Wong
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

4.  Office-based unsedated small-caliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett's esophagus: a randomized and blinded comparison.

Authors:  Blair A Jobe; John G Hunter; Eugene Y Chang; Charles Y Kim; Glenn M Eisen; Jedediah D Robinson; Brian S Diggs; Robert W O'Rourke; Anne E Rader; Paul Schipper; David A Sauer; Jeffrey H Peters; David A Lieberman; Cynthia D Morris
Journal:  Am J Gastroenterol       Date:  2006-12       Impact factor: 10.864

5.  Mobile colonoscopic surveillance provides quality care for hereditary nonpolyposis colorectal carcinoma families in South Africa.

Authors:  D W Anderson; P A Goldberg; U Algar; R Felix; R S Ramesar
Journal:  Colorectal Dis       Date:  2007-07       Impact factor: 3.788

6.  The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria.

Authors:  Prateek Sharma; John Dent; David Armstrong; Jacques J G H M Bergman; Liebwin Gossner; Yoshio Hoshihara; Janusz A Jankowski; Ola Junghard; Lars Lundell; Guido N J Tytgat; Michael Vieth
Journal:  Gastroenterology       Date:  2006-08-16       Impact factor: 22.682

7.  A randomized trial of peroral versus transnasal unsedated endoscopy using an ultrathin videoendoscope.

Authors:  A Zaman; M Hahn; R Hapke; K Knigge; M B Fennerty; R M Katon
Journal:  Gastrointest Endosc       Date:  1999-03       Impact factor: 9.427

8.  Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age.

Authors:  Linda Morris Brown; Susan S Devesa; Wong-Ho Chow
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

9.  Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study.

Authors:  R M Zagari; L Fuccio; M-A Wallander; S Johansson; R Fiocca; S Casanova; B Y Farahmand; C C Winchester; E Roda; F Bazzoli
Journal:  Gut       Date:  2008-04-18       Impact factor: 23.059

10.  A comparison of endoscopic treatment and surgery in early esophageal cancer: an analysis of surveillance epidemiology and end results data.

Authors:  Ananya Das; Vandana Singh; David E Fleischer; Virender K Sharma
Journal:  Am J Gastroenterol       Date:  2008-05-28       Impact factor: 10.864

View more
  45 in total

1.  Novel Screening Alternatives for Barrett Esophagus.

Authors:  Apoorva Krishna Chandar; Anamay Sharma; Amitabh Chak
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-05

Review 2.  Guideline on screening for esophageal adenocarcinoma in patients with chronic gastroesophageal reflux disease.

Authors:  Stéphane Groulx; Heather Limburg; Marion Doull; Scott Klarenbach; Harminder Singh; Brenda J Wilson; Brett Thombs
Journal:  CMAJ       Date:  2020-07-06       Impact factor: 8.262

Review 3.  Barrett's esophagus: diagnosis and management.

Authors:  Swathi Eluri; Nicholas J Shaheen
Journal:  Gastrointest Endosc       Date:  2017-01-18       Impact factor: 9.427

Review 4.  Optimizing the diagnosis and therapy of Barrett's esophagus.

Authors:  Juan A Muñoz-Largacha; Hiran C Fernando; Virginia R Litle
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

Review 5.  Endoscopic risk factors for neoplastic progression in patients with Barrett's oesophagus.

Authors:  Angela Bureo Gonzalez; Jacques Jghm Bergman; Roos E Pouw
Journal:  United European Gastroenterol J       Date:  2016-03-02       Impact factor: 4.623

6.  Unsedated Transnasal Endoscopy (uTNE): Not Quite Ready to Replace Sedated Esophagogastroduodenoscopy (sEGD).

Authors:  Aslam Syed; Annette Kyprianou
Journal:  Am J Gastroenterol       Date:  2015-06       Impact factor: 10.864

7.  Response to Syed et al.

Authors:  Sarmed S Sami; Krish Ragunath; Prasad G Iyer
Journal:  Am J Gastroenterol       Date:  2015-06       Impact factor: 10.864

8.  Comparative Assessment of Patient Preferences and Tolerability in Barrett Esophagus Screening: Results From a Randomized Trial.

Authors:  Christopher H Blevins; Jason S Egginton; Nilay D Shah; Michele L Johnson; Prasad G Iyer
Journal:  J Clin Gastroenterol       Date:  2018 Nov/Dec       Impact factor: 3.062

9. 

Authors:  Stéphane Groulx; Heather Limburg; Marion Doull; Scott Klarenbach; Harminder Singh; Brenda J Wilson; Brett Thombs
Journal:  CMAJ       Date:  2020-11-23       Impact factor: 8.262

Review 10.  Endoscopic Screening for Barrett's Esophagus and Esophageal Adenocarcinoma: Rationale, Candidates, and Challenges.

Authors:  Amrit K Kamboj; David A Katzka; Prasad G Iyer
Journal:  Gastrointest Endosc Clin N Am       Date:  2020-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.